Navigation Links
BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
Date:8/22/2012

BOULDER, Colo., Aug. 22, 2012 /PRNewswire/ -- BiOptix today officially announced its fall 2012 Tradeshow and Symposia schedule.  These events will highlight the BiOptix Enhanced Surface Plasmon Resonance (ESPR) technology and the forthcoming BiOptix 404pi, a novel and game-changing label-free SPR instrument for kinetic detection. BiOptix Events for fall 2012 include:

  • 34th Semiannual Biotechnology Symposia, University of California, San Diego:  August 23rd
  • HUPO – 11th Annual World Congress:  September 9 – 13th
  • BioWest 2012:   September 11th
  • MipTec:  September 25 – 27th
  • NIH Research Festival:  October 11 – 12th
  • AAPS–American Association of Pharmaceutical Scientists:  October 14 – 17th
  • 22nd Annual Bristol-Myers Squibb R&D Symposium:  October 29 – 30th
  • Label-Free Technologies–Advances and Applications:   November 1 – 3rd
  • 4th Annual PEGS-Europe Conference:  November 6 – 8th
  • Antibody Engineering–23rd Annual International Conference:   December 2 – 6th

(Logo: http://photos.prnewswire.com/prnh/20120822/LA61037LOGO)

"BiOptix is excited to be represented at and participate in some of the most prestigious scientific events in Europe and North America for the balance of 2012," noted Ken Wilczek, Vice President of Sales and Marketing for BiOptix. "2012 has been groundbreaking for BiOptix, as we have met with and presented our unique SPR technology to over 3,000 scientific researchers so far. We are enthusiastic to present the BiOptix value proposition to additional scientific researchers in the months ahead."

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Interventional Spine Announces its 75th Patient Treated with the PerX360 Percutaneous Spinal Fusion Technology
2. Precision Automation Expert DWFritz Automation Announces Website Launch www.DWFritz.com
3. CPhI South America Expands Offering for 2013, Announces Co-Location with Food Ingredients South America
4. EFJohnson Announces Impact Partner Dealer Program
5. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
6. Kallo Announces Purchase Order For Its Specialist EMR - EMCURx
7. CryoLife Announces Initiation of Quarterly Cash Dividend
8. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
9. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
10. Angeion Announces Name Change and New Trading Symbol Effective Tuesday, August 21, 2012
11. VWR Funding, Inc. Announces Proposed Offering Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)... , July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, ... program to patients who suffer from painful intercourse and other painful pelvic ... vaginal atrophy due to menopause. ... VuVatech LLC ... created by Sarasota, Florida -based start-up company, VuVatech LLC, ...
Breaking Medicine Technology:
(Date:7/24/2017)... , ... July 24, 2017 , ... SignatureCare Emergency ... will be awarded for the fall semester to a deserving student. Get your ... Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing student at ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... Oakland, California effectively destroyed the construction site and threatened numerous homes and businesses ... 7th article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider of ... with WALLIX to expand its solution to help government contractors more quickly ... number of ways to address the authentication requirements within NIST SP800-171, but no ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global leader in ... of United States Patent Number 9,695,398 (the '398 patent) and South Korean Patent ... and '324 patents cover methods and systems for optimizing fat grafts for current ...
(Date:7/24/2017)... ... July 24, 2017 , ... A new report ... on delivering end-to-end sleep health care at scale, indicates record-breaking adherence results for ... rates for positive airway pressure (PAP) therapy, the most widely utilized treatment for ...
Breaking Medicine News(10 mins):